# data[].attributes.headline
Initiator of Reaction of different types of hypersensitivity (Xinyi)

# data[].attributes.subject
Initiator of Reaction of different types of hypersensitivity (Xinyi)

# data[].attributes.body
Type 1 Hypersensitivity

Occurs after a person expose to an antigen

The body of the person responds to an antigen by producing a specific type of antibody Ig E.

Different components that can trigger Type 1 Hypersensitivity:

Food products, such as nuts, shellfish, and soy

Animal sources, such as cats, rats, or bee stings

Environmental sources, such as mold, latex, and dust

Allergic conditions (allergic rhinitis, allergic asthma, and conjunctivitis)

Type 2 Hypersensitivity

Occurs after a person expose to an antigen

The body of the person responds to an antigen by producing a specific type of antibody Ig G but also involve in Ig M.

Causes cytotoxic reactions which lead to long terms damage to cells and tissues.

Type 3 Hypersensitivity

Antigens and antibodies form complexes in the skin, blood vessels, joints, and kidney tissues.

Cause a series of reactions that lead to tissue damage.

Causes of a type 3 hypersensitivity reaction can include:

Drugs that contain proteins from different organisms (antivenins)

Drug infliximab, use to manage autoimmune conditions

Animal sources (insect stings or tick bites)

Type 4 Hypersensitivity

Reactions are cell-mediated.

Instead of antibodies, T cells control type 4 hypersensitivity reactions.

Common causes of Type 4 Hypersensitivity include:

Exposure to poison ivy

Certain metals

drugs (antibiotics or anticonvulsants)

# data[].attributes.attachment_link.title
What are the different types of hypersensitivity reactions?

# data[].attributes.attachment_link.description
What are hypersensitivity reactions, and what are the different types? Read on to learn more about these immune reactions and how they differ.

# data[].attributes.headline
Symptoms of different types of hypersensitivity. (Darius)

# data[].attributes.subject
Symptoms of different types of hypersensitivity. (Darius)

# data[].attributes.body
Type I Hypersensitivity (Immediate)

Allergic rhinitis: Sneezing, runny nose, nasal congestion, itchy eyes.

Asthma: Wheezing, shortness of breath, chest tightness.

Anaphylaxis: Rapid onset of difficulty breathing, swelling (especially of the face, lips, and throat), drop in blood pressure, hives, nausea, vomiting.

Type II Hypersensitivity (Cytotoxic)

Hemolytic anemia: Fatigue, pallor, shortness of breath, dark urine (due to hemoglobinuria), jaundice.

Goodpasture's syndrome: Hemoptysis (coughing up blood), difficulty breathing, blood in urine, kidney failure.

Myasthenia gravis: Muscle weakness, drooping eyelids, difficulty swallowing, difficulty breathing.

Type III Hypersensitivity (Immune Complex-Mediated)

Systemic lupus erythematosus (SLE): Butterfly-shaped rash on the face, joint pain, fatigue, kidney problems, photosensitivity.

Post-streptococcal glomerulonephritis: Blood in urine, swelling (edema), high blood pressure, kidney dysfunction.

Serum sickness: Fever, rash, joint pain, lymphadenopathy (swollen lymph nodes).

Type IV Hypersensitivity (Delayed-Type)

Contact dermatitis: Red, itchy rash, blisters, swelling at the site of contact with an allergen (e.g., poison ivy, nickel).

Tuberculin reaction: Red, indurated (hardened) skin at the injection site of the tuberculin test.

Chronic transplant rejection: Gradual loss of organ function (e.g., increased blood pressure, reduced urine output in kidney transplant rejection), organ-specific symptoms.

# data[].attributes.attachment_link.description
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

# data[].attributes.headline
Components of immune system involved (Jiaxin)

# data[].attributes.subject
Components of immune system involved (Jiaxin)

# data[].attributes.body
Type I Hypersensitivity (Immediate)

IgE antibodies: Produced by B cells in the response to the allergen. Binds to the Fc receptors on mast cells and basophils.

Mast cells and Basophils: Contains granules filled with histamine and other inflammatory mediators that are released upon activation by allergen-bound IgE antibody.

Histamine: Released by mast cells and basophils. Causes vasodilation, increased vascular permeability, and bronchoconstriction.

Type II Hypersensitivity (Cytotoxic)

IgG and IgM antibodies: Directed against specific antigens present on cell surfaces.

Complement system (Classical pathway): Activated by the binding of IgG and IgM on cell surfaces. Involved in the recruitment of inflammatory cells and leads to the formation of Membrane Attack Complexes (MAC) which causes cell lysis.

Macrophage and Neutrophils: Effector cells. Macrophages can be activated by antibodies bound to target cells and contribute to phagocytosis and tissue damage. Neutrophils are recruited by the complement system and contributes to tissue damage through the release of Reactive Oxygen Species (ROS) and proteolytic enzymes.

Type III Hypersensitivity (Immune-Complex Mediated)

IgG and IgM antibodies: IgG is the primary antibody involved in forming immune complexes but IgM can also be sometimes involved in immune complex formation. The antibodies bind to soluble antigens to form immune complexes.

Immune complexes (Antigen-Antibody complex): Forms when IgG or IgM binds to soluble antigens.

Macrophage and Neutrophils: Recruitment of these cells at the the places where the immune complexes are deposited. Causes inflammation reactions and tissue destruction.

Type IV Hypersensitivity (Delayed-Type)

CD4+ T Helper Cells (Th1) and CD8+ Cytotoxic T cells: T Lymphocytes. CD4+ T Helper Cells recognize antigens presented by Antigen-Presenting Cells (APCs) and release cytokines that help recruit and activate immune cells. CD8+ Cytotoxic T cells directly kill cells presenting the antigen.

Dendritic cells: Antigen-Presenting Cell (APC) that captures and presents antigens to T cells, initiating an immune response.

Macrophages: Activated macrophages releases inflammatory mediators, phagocytoses pathogens, and can act as an Antigen-Presenting Cell (APC).

# data[].attributes.attachment_link.readable_text
Page ID

5227

1. Learning Objectives

2. Clinical Focus: Part 1

3. Exercise \(\PageIndex{1}\)

4. Type I Hypersensitivities

1. Exercise \(\PageIndex{2}\)

2. The Hygiene Hypothesis

5. Type II (Cytotoxic) Hypersensitivities

6. ABO Blood Group Incompatibility

7. Rh Factors

1. Link to Learning

2. Exercise \(\PageIndex{3}\)

3. Clinical Focus: Part 2

4. Exercise \(\PageIndex{4}\)

8. Type III Hypersensitivities

1. Exercise \(\PageIndex{5}\)

2. Diphtheria Antitoxin

3. Clinical Focus: Part 3

4. Exercise \(\PageIndex{6}\)

9. Type IV Hypersensitivities

1. Exercise \(\PageIndex{7}\)

2. Using Delayed Hypersensitivity to Test for TB

10. Hypersensitivity Pneumonitis
Exercise \(\PageIndex{8}\)

11. Diagnosis of Hypersensitivities
Exercise \(\PageIndex{9}\)

12. Treatments of Hypersensitivities
Exercise \(\PageIndex{10}\)

13. Key Concepts and Summary

14. Footnotes

Learning Objectives

Identify and compare the distinguishing characteristics, mechanisms, and major examples of type I, II, III, and IV hypersensitivities

Clinical Focus: Part 1

Kerry, a 40-year-old airline pilot, has made an appointment with her primary care physician to discuss a rash that develops whenever she spends time in the sun. As she explains to her physician, it does not seem like sunburn. She is careful not to spend too much time in the sun and she uses sunscreen. Despite these precautions, the rash still appears, manifesting as red, raised patches that get slightly scaly. The rash persists for 7 to 10 days each time, and it seems to largely go away on its own. Lately, the rashes have also begun to appear on her cheeks and above her eyes on either side of her forehead.

In Adaptive Specific Host Defenses, we discussed the mechanisms by which adaptive immune defenses, both humoral and cellular, protect us from infectious diseases. However, these same protective immune defenses can also be responsible for undesirable reactions called hypersensitivity reactions. Hypersensitivity reactions are classified by their immune mechanism.

Type I hypersensitivity reactions involve immunoglobulin E (IgE) antibody against soluble antigen, triggering mast cell degranulation.

Type II hypersensitivity reactions involve IgG and IgM antibodies directed against cellular antigens, leading to cell damage mediated by other immune system effectors.

Type III hypersensitivity reactions involve the interactions of IgG, IgM, and, occasionally, IgA¹ antibodies with antigen to form immune complexes. Accumulation of immune complexes in tissue leads to tissue damage mediated by other immune system effectors.

Type IV hypersensitivity reactions are T-cell-mediated reactions that can involve tissue damage mediated by activated macrophages and cytotoxic T cells.

Type I Hypersensitivities

When a presensitized individual is exposed to an allergen, it can lead to a rapid immune response that occurs almost immediately. Such a response is called an allergy and is classified as a type I hypersensitivity. Allergens may be seemingly harmless substances such as animal dander, molds, or pollen. Allergens may also be substances considered innately more hazardous, such as insect venom or therapeutic drugs. Food intolerances can also yield allergic reactions as individuals become sensitized to foods such as peanuts or shellfish (Figure \(\PageIndex{1}\)). Regardless of the allergen, the first exposure activates a primary IgE antibody response that sensitizes an individual to type I hypersensitivity reaction upon subsequent exposure.

Figure \(\PageIndex{1}\): (a) Allergens in plant pollen, shown here in a colorized electron micrograph, may trigger allergic rhinitis or hay fever in sensitive individuals. (b) Skin rashes are often associated with allergic reactions. (c) Peanuts can be eaten safely by most people but can provoke severe allergic reactions in sensitive individuals.

For susceptible individuals, a first exposure to an allergen activates a strong T H2 cell response (Figure \(\PageIndex{2}\)). Cytokines interleukin (IL)-4 and IL-13 from the T H 2 cells activate B cells specific to the same allergen, resulting in clonal proliferation, differentiation into plasma cells, and antibody-class switch from production of IgM to production of IgE. The fragment crystallizable (Fc) regions of the IgE antibodies bind to specific receptors on the surface of mast cellsthroughout the body. It is estimated that each mast cell can bind up to 500,000 IgE molecules, with each IgE molecule having two allergen-specific fragment antigen-binding (Fab) sites available for binding allergen on subsequent exposures. By the time this occurs, the allergen is often no longer present and there is no allergic reaction, but the mast cells are primed for a subsequent exposure and the individual is sensitized to the allergen.

On subsequent exposure, allergens bind to multiple IgE molecules on mast cells, cross-linking the IgE molecules. Within minutes, this cross-linking of IgE activates the mast cells and triggers degranulation, a reaction in which the contents of the granules in the mast cell are released into the extracellular environment. Preformed components that are released from granules include histamine, serotonin, and bradykinin (Table \(\PageIndex{1}\)). The activated mast cells also release newly formed lipid mediators (leukotrienes and prostaglandins from membrane arachadonic acid metabolism) and cytokines such as tumor necrosis factor (Table \(\PageIndex{2}\)).

Granule Component

Activity

Heparin

Stimulates the generation of bradykinin, which causes increased vascular permeability, vasodilation, bronchiole constriction, and increased mucus secretion

Histamine

Causes smooth-muscle contraction, increases vascular permeability, increases mucus and tear formation

Serotonin

Increases vascular permeability, causes vasodilation and smooth-muscle contraction

The chemical mediators released by mast cells collectively cause the inflammation and signs and symptoms associated with type I hypersensitivity reactions. Histamine stimulates mucus secretion in nasal passages and tear formation from lacrimal glands, promoting the runny nose and watery eyes of allergies. Interaction of histamine with nerve endings causes itching and sneezing. The vasodilation caused by several of the mediators can result in hives, headaches, angioedema (swelling that often affects the lips, throat, and tongue), and hypotension (low blood pressure). Bronchiole constriction caused by some of the chemical mediators leads to wheezing, dyspnea (difficulty breathing), coughing, and, in more severe cases, cyanosis (bluish color to the skin or mucous membranes). Vomiting can result from stimulation of the vomiting center in the cerebellum by histamine and serotonin. Histamine can also cause relaxation of intestinal smooth muscles and diarrhea.

Chemical Mediator

Activity

Leukotriene

Causes smooth-muscle contraction and mucus secretion, increases vascular permeability

Prostaglandin

Causes smooth-muscle contraction and vasodilation

TNF-α (cytokine)

Causes inflammation and stimulates cytokine production by other cell types

Figure \(\PageIndex{2}\): On first exposure to an allergen in a susceptible individual, antigen-presenting cells process and present allergen epitopes with major histocompatibility complex (MHC) II to T helper cells. B cells also process and present the same allergen epitope to TH2 cells, which release cytokines IL-4 and IL-13 to stimulate proliferation and differentiation into IgE-secreting plasma cells. The IgE molecules bind to mast cells with their Fc region, sensitizing the mast cells for activation with subsequent exposure to the allergen. With each subsequent exposure, the allergen cross-links IgE molecules on the mast cells, activating the mast cells and causing the release of preformed chemical mediators from granules (degranulation), as well as newly formed chemical mediators that collectively cause the signs and symptoms of type I hypersensitivity reactions.

Type I hypersensitivity reactions can be either localized or systemic. Localized type I hypersensitivity reactions include hay fever rhinitis, hives, and asthma (Table \(\PageIndex{3}\)). Systemic type I hypersensitivity reactions are referred to as anaphylaxisor anaphylactic shock. Although anaphylaxis shares many symptoms common with the localized type I hypersensitivity reactions, the swelling of the tongue and trachea, blockage of airways, dangerous drop in blood pressure, and development of shock can make anaphylaxis especially severe and life-threatening. In fact, death can occur within minutes of onset of signs and symptoms.

Late-phase reactions in type I hypersensitivities may develop 4-12 hours after the early phase and are mediated by eosinophils, neutrophils, and lymphocytes that have been recruited by chemotactic factors released from mast cells. Activation of these recruited cells leads to the release of more chemical mediators that cause tissue damage and late-phase symptoms of swelling and redness of the skin, coughing, wheezing, and nasal discharge.

Individuals who possess genes for maladaptive traits, such as intense type I hypersensitivity reactions to otherwise harmless components of the environment, would be expected to suffer reduced reproductive success. With this kind of evolutionary selective pressure, such traits would not be expected to persist in a population. This suggests that type I hypersensitivities may have an adaptive function. There is evidence that the IgE produced during type I hypersensitivity reactions is actually meant to counter helminth infections². Helminths are one of few organisms that possess proteins that are targeted by IgE. In addition, there is evidence that helminth infections at a young age reduce the likelihood of type I hypersensitivities to innocuous substances later in life. Thus it may be that allergies are an unfortunate consequence of strong selection in the mammalian lineage or earlier for a defense against parasitic worms.

Common Name

Cause

Signs and Symptoms

Type II (Cytotoxic) Hypersensitivities

Immune reactions categorized as type II hypersensitivities, or cytotoxic hypersensitivities, are mediated by IgG and IgM antibodies binding to cell-surface antigens or matrix-associated antigens on basement membranes. These antibodies can either activate complement, resulting in an inflammatory response and lysis of the targeted cells, or they can be involved in antibody-dependent cell-mediated cytotoxicity (ADCC) with cytotoxic T cells.

In some cases, the antigen may be a self-antigen, in which case the reaction would also be described as an autoimmune disease. (Autoimmune diseases are described in Autoimmune Disorders). In other cases, antibodies may bind to naturally occurring, but exogenous, cell-surface molecules such as antigens associated with blood typing found on red blood cells (RBCs). This leads to the coating of the RBCs by antibodies, activation of the complement cascade, and complement-mediated lysis of RBCs, as well as opsonization of RBCs for phagocytosis. Two examples of type II hypersensitivity reactions involving RBCs are hemolytic transfusion reaction (HTR) and hemolytic disease of the newborn (HDN). These type II hypersensitivity reactions, which will be discussed in greater detail, are summarized in Table \(\PageIndex{4}\).

Immunohematology is the study of blood and blood-forming tissue in relation to the immune response. Antibody-initiated responses against blood cells are type II hypersensitivities, thus falling into the field of immunohematology. For students first learning about immunohematology, understanding the immunological mechanisms involved is made even more challenging by the complex nomenclature system used to identify different blood-group antigens, often called blood types. The first blood-group antigens either used alphabetical names or were named for the first person known to produce antibodies to the red blood cell antigen (e.g., Kell, Duffy, or Diego). However, in 1980, the International Society of Blood Transfusion (ISBT) Working Party on Terminology created a standard for blood-group terminology in an attempt to more consistently identify newly discovered blood group antigens. New antigens are now given a number and assigned to a blood-group system, collection, or series. However, even with this effort, blood-group nomenclature is still inconsistent.

Common Name

Cause

Signs and Symptoms

ABO Blood Group Incompatibility

The recognition that individuals have different blood types was first described by Karl Landsteiner (1868-1943) in the early 1900s, based on his observation that serum from one person could cause a clumping of RBCs from another. These studies led Landsteiner to the identification of four distinct blood types. Subsequent research by other scientists determined that the four blood types were based on the presence or absence of surface glycoproteins "A" and "B," and this provided the foundation for the ABO blood group system that is still in use today (Figure \(\PageIndex{3}\)). The functions of these antigens are unknown, but some have been associated with normal biochemical functions of the cell. Furthermore, ABO blood types are inherited as alleles (one from each parent), and they display patterns of dominant and codominant inheritance. The alleles for A and B blood types are codominant to each other, and both are dominant over blood type O. Therefore, individuals with genotypes of AA or AO have type A blood and express the A glycoprotein antigen on the surface of their RBCs. People with genotypes of BB or BO have type B blood and express the B glycoprotein antigen on the surface of their RBCs. Those with a genotype of AB have type AB blood and express both A and B glycoprotein antigens on the surface of their RBCs. Finally, individuals with a genotype of OO have type O blood and lack A and B glycoproteins on the surface of their RBCs.

It is important to note that the RBCs of all four ABO blood types share a common protein receptor molecule, and it is the addition of specific carbohydrates to the protein receptors that determines A, B, and AB blood types. The genes that are inherited for the A, B, and AB blood types encode enzymes that add the carbohydrate component to the protein receptor. Individuals with O blood type still have the protein receptor but lack the enzymes that would add carbohydrates that would make their red blood cell type A, B, or AB.

IgM antibodies in plasma that cross-react with blood group antigens not present on an individual's own RBCs are called isohemagglutinins (Figure \(\PageIndex{3}\)). Isohemagglutinins are produced within the first few weeks after birth and persist throughout life. These antibodies are produced in response to exposure to environmental antigens from food and microorganisms. A person with type A blood has A antigens on the surface of their RBCs and will produce anti-B antibodies to environmental antigens that resemble the carbohydrate component of B antigens. A person with type B blood has B antigens on the surface of their RBCs and will produce anti-A antibodies to environmental antigens that are similar to the carbohydrate component of A antigens. People with blood type O lack both A and B antigens on their RBCs and, therefore, produce both anti-A and anti-B antibodies. Conversely, people with AB blood type have both A and B antigens on their RBCs and, therefore, lack anti-A and anti-B antibodies.

Figure \(\PageIndex{3}\): Isohemagglutinins

A patient may require a blood transfusion because they lack sufficient RBCs (anemia) or because they have experienced significant loss of blood volume through trauma or disease. Although the blood transfusion is given to help the patient, it is essential that the patient receive a transfusion with matching ABO blood type. A transfusion with an incompatible ABO blood type may lead to a strong, potentially lethal type II hypersensitivity cytotoxic response called hemolytic transfusion reaction (HTR) (Figure \(\PageIndex{4}\)).

For instance, if a person with type B blood receives a transfusion of type A blood, their anti-A antibodies will bind to and agglutinate the transfused RBCs. In addition, activation of the classical complement cascade will lead to a strong inflammatory response, and the complement membrane attack complex (MAC) will mediate massive hemolysis of the transfused RBCs. The debris from damaged and destroyed RBCs can occlude blood vessels in the alveoli of the lungs and the glomeruli of the kidneys. Within 1 to 24 hours of an incompatible transfusion, the patient experiences fever, chills, pruritus (itching), urticaria (hives), dyspnea, hemoglobinuria (hemoglobin in the urine), and hypotension (low blood pressure). In the most serious reactions, dangerously low blood pressure can lead to shock, multi-organ failure, and death of the patient.

Hospitals, medical centers, and associated clinical laboratories typically use hemovigilance systems to minimize the risk of HTRs due to clerical error. Hemovigilance systems are procedures that track transfusion information from the donor source and blood products obtained to the follow-up of recipient patients. Hemovigilance systems used in many countries identify HTRs and their outcomes through mandatory reporting (e.g., to the Food and Drug Administration in the United States), and this information is valuable to help prevent such occurrences in the future. For example, if an HTR is found to be the result of laboratory or clerical error, additional blood products collected from the donor at that time can be located and labeled correctly to avoid additional HTRs. As a result of these measures, HTR-associated deaths in the United States occur in about one per 2 million transfused units.⁶

Figure \(\PageIndex{4}\): A type II hypersensitivity hemolytic transfusion reaction (HTR) leading to hemolytic anemia. Blood from a type A donor is administered to a patient with type B blood. The anti-A isohemagglutinin IgM antibodies in the recipient bind to and agglutinate the incoming donor type A red blood cells. The bound anti-A antibodies activate the classical complement cascade, resulting in destruction of the donor red blood cells.

Rh Factors

Many different types of erythrocyte antigens have been discovered since the description of the ABO red cell antigens. The second most frequently described RBC antigens are Rh factors, named after the rhesus macaque ( Macaca mulatta) factors identified by Karl Landsteiner and Alexander Weiner in 1940. The Rh system of RBC antigens is the most complex and immunogenic blood group system, with more than 50 specificities identified to date. Of all the Rh antigens, the one designated Rho (Weiner) or D (Fisher-Race) is the most immunogenic. Cells are classified as Rh positive (Rh+) if the Rho/D antigen is present or as Rh negative (Rh−) if the Rho/D antigen is absent. In contrast to the carbohydrate molecules that distinguish the ABO blood groups and are the targets of IgM isohemagglutinins in HTRs, the Rh factor antigens are proteins. As discussed in B Lymphocytes and Humoral Immunity, protein antigens activate B cells and antibody production through a T-cell-dependent mechanism, and the T H2 cells stimulate class switching from IgM to other antibody classes. In the case of Rh factor antigens, T H 2 cells stimulate class switching to IgG, and this has important implications for the mechanism of HDN.

Like ABO incompatibilities, blood transfusions from a donor with the wrong Rh factor antigens can cause a type II hypersensitivity HTR. However, in contrast to the IgM isohemagglutinins produced early in life through exposure to environmental antigens, production of anti-Rh factor antibodies requires the exposure of an individual with Rh− blood to Rh+ positive RBCs and activation of a primary antibody response. Although this primary antibody response can cause an HTR in the transfusion patient, the hemolytic reaction would be delayed up to 2 weeks during the extended lag period of a primary antibody response ( B Lymphocytes and Humoral Immunity). However, if the patient receives a subsequent transfusion with Rh+ RBCs, a more rapid HTR would occur with anti-Rh factor antibody already present in the blood. Furthermore, the rapid secondary antibody response would provide even more anti-Rh factor antibodies for the HTR.

Rh factor incompatibility between mother and fetus can also cause a type II hypersensitivity hemolytic reaction, referred to as hemolytic disease of the newborn (HDN) (Figure \(\PageIndex{5}\)). If an Rh− woman carries an Rh+ baby to term, the mother's immune system can be exposed to Rh+ fetal red blood cells. This exposure will usually occur during the last trimester of pregnancy and during the delivery process. If this exposure occurs, the Rh+ fetal RBCs will activate a primary adaptive immune response in the mother, and anti-Rh factor IgG antibodies will be produced. IgG antibodies are the only class of antibody that can cross the placenta from mother to fetus; however, in most cases, the first Rh+ baby is unaffected by these antibodies because the first exposure typically occurs late enough in the pregnancy that the mother does not have time to mount a sufficient primary antibody response before the baby is born.

If a subsequent pregnancy with an Rh+ fetus occurs, however, the mother's second exposure to the Rh factor antigens causes a strong secondary antibody response that produces larger quantities of anti-Rh factor IgG. These antibodies can cross the placenta from mother to fetus and cause HDN, a potentially lethal condition for the baby (Figure \(\PageIndex{5}\)).

Prior to the development of techniques for diagnosis and prevention, Rh factor incompatibility was the most common cause of HDN, resulting in thousands of infant deaths each year worldwide.⁷ For this reason, the Rh factors of prospective parents are regularly screened, and treatments have been developed to prevent HDN caused by Rh incompatibility. To prevent Rh factor-mediated HDN, human Rho(D) immune globulin (e.g., RhoGAM) is injected intravenously or intramuscularly into the mother during the 28th week of pregnancy and within 72 hours after delivery. Additional doses may be administered after events that may result in transplacental hemorrhage (e.g., umbilical blood sampling, chorionic villus sampling, abdominal trauma, amniocentesis). This treatment is initiated during the first pregnancy with an Rh+ fetus. The anti-Rh antibodies in Rho(D) immune globulin will bind to the Rh factor of any fetal RBCs that gain access to the mother's bloodstream, preventing these Rh+ cells from activating the mother's primary antibody response. Without a primary anti-Rh factor antibody response, the next pregnancy with an Rh+ will have minimal risk of HDN. However, the mother will need to be retreated with Rho(D) immune globulin during that pregnancy to prevent a primary anti-Rh antibody response that could threaten subsequent pregnancies.

Figure \(\PageIndex{5}\): (a) When an Rh− mother has an Rh+ fetus, fetal erythrocytes are introduced into the mother's circulatory system before or during birth, leading to production of anti-Rh IgG antibodies. These antibodies remain in the mother and, if she becomes pregnant with a second Rh+ baby, they can cross the placenta and attach to fetal Rh+ erythrocytes. Complement-mediated hemolysis of fetal erythrocytes results in a lack of sufficient cells for proper oxygenation of the fetus. (b) HDN can be prevented by administering Rho(D) immune globulin during and after each pregnancy with an Rh+ fetus. The immune globulin binds fetal Rh+ RBCs that gain access to the mother's bloodstream, preventing activation of her primary immune response.

Type III Hypersensitivities

Type III hypersensitivities are immune-complex reactions that were first characterized by Nicolas Maurice Arthus (1862-1945) in 1903. To produce antibodies for experimental procedures, Arthus immunized rabbits by injecting them with serum from horses. However, while immunizing rabbits repeatedly with horse serum, Arthus noticed a previously unreported and unexpected localized subcutaneous hemorrhage with edema at the site of injection. This reaction developed within 3 to10 hours after injection. This localized reaction to non-self serum proteins was called an Arthus reaction. An Arthus reaction occurs when soluble antigens bind with IgG in a ratio that results in the accumulation of antigen-antibody aggregates called immune complexes.

A unique characteristic of type III hypersensitivity is antibody excess (primarily IgG), coupled with a relatively low concentration of antigen, resulting in the formation of small immune complexes that deposit on the surface of the epithelial cells lining the inner lumen of small blood vessels or on the surfaces of tissues (Figure \(\PageIndex{6}\)). This immune complex accumulation leads to a cascade of inflammatory events that include the following:

1. IgG binding to antibody receptors on localized mast cells, resulting in mast-cell degranulation

2. Complement activation with production of pro-inflammatory C3a and C5a (see Chemical Defenses)

3. Increased blood-vessel permeability with chemotactic recruitment of neutrophils and macrophages

Because these immune complexes are not an optimal size and are deposited on cell surfaces, they cannot be phagocytosed in the usual way by neutrophils and macrophages, which, in turn, are often described as "frustrated." Although phagocytosis does not occur, neutrophil degranulation results in the release of lysosomal enzymes that cause extracellular destruction of the immune complex, damaging localized cells in the process. Activation of coagulation pathways also occurs, resulting in thrombi (blood clots) that occlude blood vessels and cause ischemia that can lead to vascular necrosis and localized hemorrhage.

Systemic type III hypersensitivity (serum sickness) occurs when immune complexes deposit in various body sites, resulting in a more generalized systemic inflammatory response. These immune complexes involve non-self proteins such as antibodies produced in animals for artificial passive immunity (see Vaccines), certain drugs, or microbial antigens that are continuously released over time during chronic infections (e.g., subacute bacterial endocarditis, chronic viral hepatitis). The mechanisms of serum sickness are similar to those described in localized type III hypersensitivity but involve widespread activation of mast cells, complement, neutrophils, and macrophages, which causes tissue destruction in areas such as the kidneys, joints, and blood vessels. As a result of tissue destruction, symptoms of serum sickness include chills, fever, rash, vasculitis, and arthritis. Development of glomerulonephritis or hepatitis is also possible.

Autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis can also involve damaging type III hypersensitivity reactions when auto-antibodies form immune complexes with self antigens. These conditions are discussed in Autoimmune Disorders.

Figure \(\PageIndex{6}\): Type III hypersensitivities and the systems they affect. (a) Immune complexes form and deposit in tissue. Complement activation, stimulation of an inflammatory response, and recruitment and activation of neutrophils result in damage to blood vessels, heart tissue, joints, skin, and/or kidneys. (b) If the kidneys are damaged by a type III hypersensitivity reaction, dialysis may be required.

Type IV Hypersensitivities

Type IV hypersensitivities are not mediated by antibodies like the other three types of hypersensitivities. Rather, type IV hypersensitivities are regulated by T cells and involve the action of effector cells. These types of hypersensitivities can be organized into three subcategories based on T-cell subtype, type of antigen, and the resulting effector mechanism (Table \(\PageIndex{5}\)).

In the first type IV subcategory, CD4 T H1-mediated reactions are described as delayed-type hypersensitivities (DTH). The sensitization step involves the introduction of antigen into the skin and phagocytosis by local antigen presenting cells (APCs). The APCs activate helper T cells, stimulating clonal proliferation and differentiation into memory T H1 cells. Upon subsequent exposure to the antigen, these sensitized memory T H1 cells release cytokines that activate macrophages, and activated macrophages are responsible for much of the tissue damage. Examples of this T H 1-mediated hypersensitivity are observed in tuberculin the Mantoux skin test and contact dermatitis, such as occurs in latex allergy reactions.

In the second type IV subcategory, CD4 T H 2-mediated reactions result in chronic asthma or chronic allergic rhinitis. In these cases, the soluble antigen is first inhaled, resulting in eosinophil recruitment and activation with the release of cytokines and inflammatory mediators.

In the third type IV subcategory, CD8 cytotoxic T lymphocyte (CTL)-mediated reactions are associated with tissue transplant rejection and contact dermatitis (Figure \(\PageIndex{7}\)). For this form of cell-mediated hypersensitivity, APCs process and present the antigen with MHC I to naïve CD8 T cells. When these naïve CD8 T cells are activated, they proliferate and differentiate into CTLs. Activated T H 1 cells can also enhance the activation of the CTLs. The activated CTLs then target and induce granzyme-mediated apoptosis in cells presenting the same antigen with MHC I. These target cells could be "self" cells that have absorbed the foreign antigen (such as with contact dermatitis due to poison ivy), or they could be transplanted tissue cells displaying foreign antigen from the donor.

Figure \(\PageIndex{7}\): Exposure to hapten antigens in poison ivy can cause contact dermatitis, a type IV hypersensitivity. (a) The first exposure to poison ivy does not result in a reaction. However, sensitization stimulates helper T cells, leading to production of memory helper T cells that can become reactivated on future exposures. (b) Upon secondary exposure, the memory helper T cells become reactivated, producing inflammatory cytokines that stimulate macrophages and cytotoxic T cells to induce an inflammatory lesion at the exposed site. This lesion, which will persist until the allergen is removed, can inflict significant tissue damage if it continues long enough.

Subcategory

Antigen

Effector Mechanism

Examples

1

Soluble antigen

Activated macrophages damage tissue and promote inflammatory response

Contact dermatitis (e.g., exposure to latex) and delayed-type hypersensitivity (e.g., tuberculin reaction)

2

Soluble antigen

Eosinophil recruitment and activation release cytokines and pro-inflammatory chemicals

Chronic asthma and chronic allergic rhinitis

3

Cell-associated antigen

CTL-mediated cytotoxicity

Contact dermatitis (e.g., contact with poison ivy) and tissue-transplant rejection

Figure \(\PageIndex{8}\): The modern version of Pirquet's scarification is the tine test, which uses devices like this to administer tuberculin antigen into the skin, usually on the inside of the forearm. The tine test is considered less reliable than the Mantoux test. (credit: modification of work by the Centers for Disease Control and Prevention)

Hypersensitivity Pneumonitis

Some disease caused by hypersensitivities are not caused exclusively by one type. For example, hypersensitivity pneumonitis (HP), which is often an occupational or environmental disease, occurs when the lungs become inflamed due to an allergic reaction to inhaled dust, endospores, bird feathers, bird droppings, molds, or chemicals. HP goes by many different names associated with various forms of exposure (Figure \(\PageIndex{9}\)). HP associated with bird droppings is sometimes called pigeon fancier's lung or poultry worker's lung-both common in bird breeders and handlers. Cheese handler's disease, farmer's lung, sauna takers' disease, and hot-tub lung are other names for HP associated with exposure to molds in various environments.

Pathology associated with HP can be due to both type III (mediated by immune complexes) and type IV (mediated by T H1 cells and macrophages) hypersensitivities. Repeated exposure to allergens can cause alveolitis due to the formation of immune complexes in the alveolar wall of the lung accompanied by fluid accumulation, and the formation of granulomas and other lesions in the lung as a result of T H 1-mediated macrophage activation. Alveolitis with fluid and granuloma formation results in poor oxygen perfusion in the alveoli, which, in turn, can cause symptoms such as coughing, dyspnea, chills, fever, sweating, myalgias, headache, and nausea. Symptoms may occur as quickly as 2 hours after exposure and can persist for weeks if left untreated.

Figure \(\PageIndex{9}\): Occupational exposure to dust, mold, and other allergens can result in hypersensitivity pneumonitis. (a) People exposed daily to large numbers of birds may be susceptible to poultry worker's lung. (b) Workers in a cheese factory may become sensitized to different types of molds and develop cheese handler's disease. (credit a: modification of work by The Global Orphan Project)

Figure \(\PageIndex{10}\) summarizes the mechanisms and effects of each type of hypersensitivity discussed in this section.

Figure \(\PageIndex{10}\): Components of the immune system cause four types of hypersensitivities. Notice that types I-III are B-cell/antibody-mediated hypersensitivities, whereas type IV hypersensitivity is exclusively a T-cell phenomenon.

Diagnosis of Hypersensitivities

Diagnosis of type I hypersensitivities is a complex process requiring several diagnostic tests in addition to a well-documented patient history. Serum IgE levels can be measured, but elevated IgE alone does not confirm allergic disease. As part of the process to identify the antigens responsible for a type I reaction allergy, testing through a prick puncture skin test (PPST) or an intradermal test can be performed. PPST is carried out with the introduction of allergens in a series of superficial skin pricks on the patient's back or arms (Figure \(\PageIndex{11}\)). PPSTs are considered to be the most convenient and least expensive way to diagnose allergies, according to the US Joint Council of Allergy and the European Academy of Allergy and Immunology. The second type of testing, the intradermal test, requires injection into the dermis with a small needle. This needle, also known as a tuberculin needle, is attached to a syringe containing a small amount of allergen. Both the PPST and the intradermal tests are observed for 15-20 minutes for a wheal-flare reaction to the allergens. Measurement of any wheal (a raised, itchy bump) and flare (redness) within minutes indicates a type I hypersensitivity, and the larger the wheal-flare reaction, the greater the patient's sensitivity to the allergen.

Type III hypersensitivities can often be misdiagnosed because of their nonspecific inflammatory nature. The symptoms are easily visible, but they may be associated with any of a number of other diseases. A strong, comprehensive patient history is crucial to proper and accurate diagnosis. Tests used to establish the diagnosis of hypersensitivity pneumonitis (resulting from type III hypersensitivity) include bronchoalveolar lavage (BAL), pulmonary function tests, and high-resolution computed tomography (HRCT).

Figure \(\PageIndex{11}\): Results of an allergy skin-prick test to test for type I hypersensitivity to a group of potential allergens. A positive result is indicated by a raised area (wheal) and surrounding redness (flare). (credit: modification of work by "OakleyOriginals"/Flickr)

Treatments of Hypersensitivities

Allergic reactions can be treated in various ways. Prevention of allergic reactions can be achieved by desensitization(hyposensitization) therapy, which can be used to reduce the hypersensitivity reaction through repeated injections of allergens. Extremely dilute concentrations of known allergens (determined from the allergen tests) are injected into the patient at prescribed intervals (e.g., weekly). The quantity of allergen delivered by the shots is slowly increased over a buildup period until an effective dose is determined and that dose is maintained for the duration of treatment, which can last years. Patients are usually encouraged to remain in the doctor's office for 30 minutes after receiving the injection in case the allergens administered cause a severe systemic reaction. Doctors' offices that administer desensitization therapy must be prepared to provide resuscitation and drug treatment in the case of such an event.

Desensitization therapy is used for insect sting allergies and environmental allergies. The allergy shots elicit the production of different interleukins and IgG antibody responses instead of IgE. When excess allergen-specific IgG antibodies are produced and bind to the allergen, they can act as blocking antibodies to neutralize the allergen before it can bind IgE on mast cells. There are early studies using oral therapy for desensitization of food allergies that are promising.¹¹ ¹² These studies involve feeding children who have allergies tiny amounts of the allergen (e.g., peanut flour) or related proteins over time. Many of the subjects show reduced severity of reaction to the food allergen after the therapy.

There are also therapies designed to treat severe allergic reactions. Emergency systemic anaphylaxis is treated initially with an epinephrine injection, which can counteract the drop in blood pressure. Individuals with known severe allergies often carry a self-administering auto-injector that can be used in case of exposure to the allergen (e.g., an insect sting or accidental ingestion of a food that causes a severe reaction). By self-administering an epinephrine shot (or sometimes two), the patient can stem the reaction long enough to seek medical attention. Follow-up treatment generally involves giving the patient antihistamines and slow-acting corticosteroids for several days after the reaction to prevent potential late-phase reactions. However, the effects of antihistamine and corticosteroid treatment are not well studied and are used based on theoretical considerations.

Treatment of milder allergic reactions typically involves antihistamines and other anti-inflammatory drugs. A variety of antihistamine drugs are available, in both prescription and over-the-counter strengths. There are also antileukotriene and antiprostaglandin drugs that can be used in tandem with antihistamine drugs in a combined (and more effective) therapy regime.

Treatments of type III hypersensitivities include preventing further exposure to the antigen and the use of anti-inflammatory drugs. Some conditions can be resolved when exposure to the antigen is prevented. Anti-inflammatory corticosteroid inhalers can also be used to diminish inflammation to allow lung lesions to heal. Systemic corticosteroid treatment, oral or intravenous, is also common for type III hypersensitivities affecting body systems. Treatment of hypersensitivity pneumonitis includes avoiding the allergen, along with the possible addition of prescription steroids such as prednisone to reduce inflammation.

Treatment of type IV hypersensitivities includes antihistamines, anti-inflammatory drugs, analgesics, and, if possible, eliminating further exposure to the antigen.

Key Concepts and Summary

An allergy is an adaptive immune response, sometimes life-threatening, to an allergen.

Type I hypersensitivity requires sensitization of mast cells with IgE, involving an initial IgE antibody response and IgE attachment to mast cells. On second exposure to an allergen, cross-linking of IgE molecules on mast cells triggers degranulation and release of preformed and newly formed chemical mediators of inflammation. Type I hypersensitivity may be localized and relatively minor (hives and hay fever) or system-wide and dangerous (systemic anaphylaxis).

Type II hypersensitivities result from antibodies binding to antigens on cells and initiating cytotoxic responses. Examples include hemolytic transfusion reaction and hemolytic disease of the newborn.

Type III hypersensitivities result from formation and accumulation of immune complexes in tissues, stimulating damaging inflammatory responses.

Type IV hypersensitivities are not mediated by antibodies, but by helper T-cell activation of macrophages, eosinophils, and cytotoxic T cells.

Footnotes

1. 1 D.S. Strayer et al (eds). Rubin's Pathology: Clinicopathologic Foundations of Medicine. 7th ed. 2Philadelphia, PA: Lippincott, Williams & Wilkins, 2014.

2. 2 C.M. Fitzsimmons et al. "Helminth Allergens, Parasite-Specific IgE, and Its Protective Role in Human Immunity." Frontier in Immunology 5 (2015):47.

3. 3 S.T. Weiss. "Eat Dirt-The Hygiene Hypothesis and Allergic Diseases." New England Journal of Medicine 347 no. 12 (2002):930-931.

4. 4 D.P. Strachan "Hay Fever, Hygiene, and Household Size." British Medical Journal 299 no. 6710 (1989):1259.

5. 5 H. Okada et al. "The 'Hygiene Hypothesis' for Autoimmune and Allergic Diseases: An Update." Clinical & Experimental Immunology 160 no. 1 (2010):1-9.

6. 6 E.C. Vamvakas, M.A. Blajchman. "Transfusion-Related Mortality: The Ongoing Risks of Allogeneic Blood Transfusion and the Available Strategies for Their Prevention." Blood 113 no. 15 (2009):3406-3417.

7. 7 G. Reali. "Forty Years of Anti-D Immunoprophylaxis." Blood Transfusion 5 no. 1 (2007):3-6.

8. 8 Centers for Disease Control and Prevention. "Diphtheria Antitoxin." http://www.cdc.gov/diphtheria/dat.html. Accessed March 25, 2016.

9. 9 B. Huber "100 Jahre Allergie: Clemens von Pirquet-sein Allergiebegriff und das ihm zugrunde liegende Krankheitsverständnis." Wiener Klinische Wochenschrift 118 no. 19-20 (2006):573-579.

10. 10 C.A. Stewart. "The Pirquet Test: Comparison of the Scarification and the Puncture Methods of Application." Archives of Pediatrics & Adolescent Medicine 35 no. 3 (1928):388-391.

11. 11 C.L. Schneider et al. "A Pilot Study of Omalizumab to Facilitate Rapid Oral Desensitization in High-Risk Peanut-Allergic Patients." Journal of Allergy and Clinical Immunology 132 no. 6 (2013):1368-1374.

12. 12 P. Varshney et al. "A Randomized Controlled Study of Peanut Oral Immunotherapy: Clinical Desensitization and Modulation of the Allergic Response." Journal of Allergy and Clinical Immunology 127 no. 3 (2011):654-660.

Back to top

Was this article helpful?

Yes

No

# data[].attributes.attachment_link.description
An allergy is an adaptive immune response, sometimes life-threatening, to an allergen. Hypersensitivity reactions are classified by their immune mechanism.

# data[].attributes.body
Type I Hypersensitivity:

Adrenaline, or epinephrine, which is used in emergency situations to counteract anaphylaxis by relaxing muscles in the airways and tightening blood vessels.

Systemic glucocorticoids, which reduces inflammation and suppress immune response.

Antihistamines, which blocks histamine receptors to reduce symptoms.

Type II Hypersensitivity:

Systemic glucocorticoids, which reduces inflammation and suppress immune response.

Cyclophosphamide and cyclosporin agents, which inhibits the immune response to prevent damage to target cells.

Intravenous immunoglobulin infusions, which administering pooled immunoglobulins to moderate the immune response.

Plasmapheresis, which helps removing circulating antibodies from the blood.

# data[].attributes.attachment_link.title
What are the different types of hypersensitivity reactions?

# data[].attributes.attachment_link.description
What are hypersensitivity reactions, and what are the different types? Read on to learn more about these immune reactions and how they differ.

# data[].attributes.body
Type III Hypersensitivity (Immune complex mediated)

SLE

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Used for joint pain and pleurisy.

Corticosteroids: Low doses such as prednisone for inflammation.

Immunosuppressive Agents: Medications like cyclophosphamide and mycophenolate are used, especially in cases of lupus nephritis.

Antimalarials: Hydroxychloroquine is often prescribed to manage skin and joint symptoms.

Biologics: Belimumab is a biologic drug that can help reduce disease activity

Post-Streptococcal Glomerulonephritis

Antibiotics: To eliminate any remaining streptococcal bacteria.

Diuretics: To reduce swelling (edema) by removing excess fluid from the body.

Antihypertensives: To manage high blood pressure.

Corticosteroids: In severe cases, to reduce inflammation.

Serum Sickness

Antihistamines: To manage allergic symptoms.

Corticosteroids: To reduce severe inflammation.

Analgesics: For pain relief.

Plasmapheresis: In severe cases, to remove immune complexes from the blood.

Type IV hypersensitivity (Delayed)

Contact Dermatitis

Topical Steroids: To reduce inflammation and itching.

Emollients: To moisturize and protect the skin.

Avoidance: Identifying and avoiding the allergen is crucial.

Tuberculin Reaction

Topical Steroids: To reduce inflammation.

Antihistamines: For itching and discomfort.

Chronic Transplant Rejection

Immunosuppressive Drugs: Such as tacrolimus, cyclosporine, and mycophenolate.

Corticosteroids: To reduce inflammation.

Regular Monitoring: To detect early signs of rejection and adjust treatment accordingly.

Ref for type 4:

https://www.ncbi.nlm.nih.gov/books/NBK562228/

# data[].attributes.attachment_link.title
Lupus Rash: Types, Causes, Treatment & Prevention

# data[].attributes.attachment_link.description
Cutaneous (skin) lupus causes skin rashes. A butterfly-shaped malar face rash is common. You may also have circular (discoid) rashes on your body.